Overall, we suggest that a rational design of cancer immunotherapy mediated by CD4+ T cells in the elderly can be administered concurrently with temporal neutralization of IL-6 activity to restore the defective Th1 development without adversely affecting their antitumour activities. The gene discussed is IL6; the disease is cancer.